Patents by Inventor Jerry M. Collins
Jerry M. Collins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7175830Abstract: The use of radio-labeled antitumor drugs in the treatment of solid tumors by the method of administering a radio-labeled anticancer drug to a patient and imaging at least a part of the patient using Positron Emission Tomography imaging is described. The method can be used to monitor delivery of antitumor drugs to tumors, to predict the effectiveness of therapy with a particular antitumor drug or combination of antitumor drugs, to assess the effectiveness of modulators of cellular accumulation, to individualize therapy and to evaluate the effectiveness of antitumor drugs with respect to particular cancers. Particularly preferred drugs are labeled taxanes, e.g., 11C-paclitaxel and 11C-docetaxel, labeled anthracyclines, e.g., 11C-doxorubicin and 11C-epirubicin, and other radiolabeled drugs, e.g. 11C-topotecan, 11C-SN-38, and 11C-imatinib. The invention further describes antitumor drugs labeled with the radioactive label 11C and methods of preparing radio-labeled drugs.Type: GrantFiled: December 16, 2002Date of Patent: February 13, 2007Assignee: The United States of America as represented by the Secretary of Health and Human ServicesInventors: Jerry M. Collins, Raymond W. Klecker, Jr., Lawrence W. Anderson
-
Patent number: 7141234Abstract: The present invention describes the use of radio-labeled antitumor drugs in the treatment of solid tumors by the method of administering a radio-labelled anticancer drug to a patient and imaging at least a part of the patient using Positron Emission Tomography imaging. The method is used to monitor delivery of antitumor drugs to tumors and may be used to predict the effectiveness of therapy with a particular antitumor drug or combination of antitumor drugs, to assess the effectiveness of modulators of cellular accumulation, to individualize therapy and to evaluate the effectiveness of antitumor drugs with respect to particular cancers. Particularly preferred drugs are labeled taxanes, e.g., 11C-paclitaxel and 11C-docetaxel, labeled anthracyclines, e.g., 11C-doxorubicin and 11C-epirubicin, and other radio-labeled drug, e.g. 11C-topotecan and 11C-mitoxantrone. The invention further describes antitumor drugs labeled with the radioactive label 11C and methods of preparing radio-labeled drugs.Type: GrantFiled: September 21, 2000Date of Patent: November 28, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jerry M. Collins, Raymond W. Klecker, Lawrence Anderson
-
Publication number: 20040157867Abstract: Thymine analogs and methods for their use as diagnostic and therapeutic agents for tumors.Type: ApplicationFiled: March 8, 2004Publication date: August 12, 2004Inventors: Raymond W. Klecker, Jerry M. Collins
-
Patent number: 6753309Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: GrantFiled: April 16, 2002Date of Patent: June 22, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Patent number: 6703374Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: GrantFiled: April 28, 2000Date of Patent: March 9, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Patent number: 6683045Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: GrantFiled: August 30, 2001Date of Patent: January 27, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Patent number: 6682715Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analog which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analog compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: GrantFiled: August 30, 2001Date of Patent: January 27, 2004Assignee: The United States of Americas as represented by the Department of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Patent number: 6677315Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: GrantFiled: August 30, 2001Date of Patent: January 13, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Patent number: 6677314Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier.Type: GrantFiled: August 30, 2001Date of Patent: January 13, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Publication number: 20030198594Abstract: The use of radio-labeled antitumor drugs in the treatment of solid tumors by the method of administering a radio-labeled anticancer drug to a patient and imaging at least a part of the patient using Positron Emission Tomography imaging is described. The method can be used to monitor delivery of antitumor drugs to tumors, to predict the effectiveness of therapy with a particular antitumor drug or combination of antitumor drugs, to assess the effectiveness of modulators of cellular accumulation, to individualize therapy and to evaluate the effectiveness of antitumor drugs with respect to particular cancers. Particularly preferred drugs are labeled taxanes, e.g., 11C-paclitaxel and 11C-docetaxel, labeled anthracyclines, e.g., 11C-doxorubicin and 11C-epirubicin, and other radiolabeled drugs, e.g. 11C-topotecan, 11C-SN-38, and 11C-imatinib. The invention further describes antitumor drugs labeled with the radioactive label 11C and methods of preparing radio-labeled drugs.Type: ApplicationFiled: December 16, 2002Publication date: October 23, 2003Inventors: Jerry M. Collins, Raymond W. Klecker, Lawrence W. Anderson
-
Publication number: 20030095921Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: ApplicationFiled: August 30, 2001Publication date: May 22, 2003Applicant: The Government of the United States of America, Secretary of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Publication number: 20030049201Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: ApplicationFiled: August 30, 2001Publication date: March 13, 2003Applicant: The Government of the United States of America, Secretary of Health and human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Publication number: 20020165199Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: ApplicationFiled: April 16, 2002Publication date: November 7, 2002Applicant: The Gov. of the USA respresented by the Secretary of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Publication number: 20020119094Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: ApplicationFiled: August 30, 2001Publication date: August 29, 2002Applicant: The Government of the United States of America, Secretary of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Patent number: 6423696Abstract: The present invention is directed to a method of inhibiting arylamine N-acetyl transferase (NAT) from acetylating an arylamine group in a substrate. The method comprises contacting NAT with an inhibitor that interacts with NAT and thereby inhibits NAT from acetylating said arylamine group in said substrate. Preferably, NAT is in vivo, such as in a mammal, and the substrate is a drug. Preferably, the method inhibits acetylation of arylamine substrates which are inhaled, ingested, or absorbed through the skin, wherein acetylation of the substrate predisposes a mammal to a biological disorder or a disease. The present invention also provides a composition comprising a compound comprising an arylamine group and an inhibitor, wherein the inhibitor interacts with NAT to inhibit NAT from acetylating the arylamine group in the compound.Type: GrantFiled: April 14, 2000Date of Patent: July 23, 2002Assignee: The United States of America, as represented by the Department of Health & Human ServicesInventors: Jerry M. Collins, Raymond W. Klecker, Aspandiar G. Katki
-
Publication number: 20020034473Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: ApplicationFiled: August 30, 2001Publication date: March 21, 2002Inventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Publication number: 20020022001Abstract: Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.Type: ApplicationFiled: August 30, 2001Publication date: February 21, 2002Applicant: The Government of the United States of America, Secretary of Health and Human ServicesInventors: Raymond W. Klecker, Lawrence Anderson, Aspandiar G. Katki, Jerry M. Collins
-
Patent number: 6235761Abstract: Substantially pure 3,5-dichloro-2-nethoxy-4-hydroxy-6-(trichloromethyl)pyridine or 4-demethylpenclomedine (formula I), acid addition salts thereof, pharmaceutical compositions containing the aforesaid compound, and a method of using the compound in the treatment of cancer in a mammal are disclosed.Type: GrantFiled: February 22, 1999Date of Patent: May 22, 2001Inventors: Neil Hartman, Robert F. Struck, Seamus O'Reilly, John M. Strong, Eric K. Rowinsky, Jerry M. Collins
-
Patent number: 4384552Abstract: A gas producing and handling system is provided comprising a rigid reservoir enclosure containing a continuous and variable supply of gaseous fuels and a suitable engine capable of utilizing the total amount of fuel provided by the gas supply for producing electrical energy. The gas supply comprises an anaerobic digester adapted to receive organic waste and which is in gaseous flow communication with the engine. The engine has a supply regulated throttle responsive to gaseous pressure in the anaerobic digester. Upon the increased production of gas such that the gaseous pressure in the digester increases, the throttle regulator controls the throttle setting of the engine to increase the output of the engine to fully use the gas supplied by the digester, thereby eliminating the need for auxiliary gas storage devices.Type: GrantFiled: April 27, 1982Date of Patent: May 24, 1983Assignee: Perennial Energy, Inc.Inventors: Frederick W. Landers, Jerry M. Collins, David Jessee